GB201616839D0 - Therapeutic compounds - Google Patents

Therapeutic compounds

Info

Publication number: GB201616839D0
Authority: GB; United Kingdom
Prior art keywords: therapeutic compounds; therapeutic; compounds
Prior art date: 2016-10-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB1616839.5A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda Pharmaceutical Co Ltd

Original Assignee

Takeda Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-10-04

Filing date

2016-10-04

Publication date

2016-11-16

2016-10-04 Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd

2016-10-04 Priority to GBGB1616839.5A priority Critical patent/GB201616839D0/en

2016-11-16 Publication of GB201616839D0 publication Critical patent/GB201616839D0/en

2017-10-04 Priority to PCT/JP2017/036899 priority patent/WO2018066718A1/en

Status Ceased legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

GBGB1616839.5A 2016-10-04 2016-10-04 Therapeutic compounds Ceased GB201616839D0 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GBGB1616839.5A GB201616839D0 (en)	2016-10-04	2016-10-04	Therapeutic compounds
PCT/JP2017/036899 WO2018066718A1 (en)	2016-10-04	2017-10-04	Therapeutic compounds

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB1616839.5A GB201616839D0 (en)	2016-10-04	2016-10-04	Therapeutic compounds

Publications (1)

Publication Number	Publication Date
GB201616839D0 true GB201616839D0 (en)	2016-11-16

Family

ID=57571164

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB1616839.5A Ceased GB201616839D0 (en)	2016-10-04	2016-10-04	Therapeutic compounds

Country Status (2)

Country	Link
GB (1)	GB201616839D0 (en)
WO (1)	WO2018066718A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE060914T2 (en) *	2017-06-22	2023-04-28	Pfizer	Dihydro-pyrrolo-pyridine derivatives
CN116323623B (en)	2020-09-18	2025-09-26	拜耳公司	Pyrido[2,3-d]pyrimidin-4-amines as SOS1 inhibitors
EP4074317A1 (en)	2021-04-14	2022-10-19	Bayer AG	Phosphorus derivatives as novel sos1 inhibitors
AU2023214467A1 (en) *	2022-02-02	2024-07-11	Katholieke Universiteit Leuven	Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
EP4634193A1 (en) *	2022-12-16	2025-10-22	Karuna Therapeutics, Inc.	Substituted dihydropyrrolo[3, 4-d]pyrimidine compounds and their use in treating medical conditions
PE20252584A1 (en)	2022-12-16	2025-11-11	Karuna Therapeutics Inc	SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
WO2024130068A1 (en) *	2022-12-16	2024-06-20	Karuna Therapeutics, Inc.	Substituted dihydropyrrolo [3, 4-d] pyrimidine compounds and their use in treating medical conditions
WO2024260386A1 (en)	2023-06-20	2024-12-26	西藏海思科制药有限公司	Muscarinic m4 receptor agonist and use thereof
TW202527956A (en) *	2023-12-07	2025-07-16	美商阿卡蒂亞藥品公司	M4 positive allosteric modulators
WO2025122809A1 (en) *	2023-12-07	2025-06-12	Acadia Pharmaceuticals Inc.	M4 positive allosteric modulators
WO2025131049A1 (en) *	2023-12-21	2025-06-26	Ignis Therapeutics (Suzhou) Limited	Dihydro-pyrrolo-pyridine derivatives and uses thereof
WO2025134078A1 (en)	2023-12-22	2025-06-26	Suven Life Sciences Limited	Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)
WO2025188974A1 (en) *	2024-03-06	2025-09-12	Ovid Therapeutics Inc.	Fused amino pyrimidine compounds for treatment of autism spectrum disorder, obsessive compulsive disorder and tics
US20250281498A1 (en) *	2024-03-06	2025-09-11	Ovid Therapeutics Inc.	Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies
WO2025188955A1 (en) *	2024-03-06	2025-09-12	Ovid Therapeutics Inc.	Fused amino pyrimidine compounds for treatment of psychosis and psychotic disorders
US20250281499A1 (en) *	2024-03-06	2025-09-11	Ovid Therapeutics Inc.	Fused amino pyrimidine compounds for treatment of neuropathic and neuro-inflammatory pain
WO2025188977A1 (en) *	2024-03-06	2025-09-12	Ovid Therapeutics Inc.	Fused amino pyrimidine compounds for treatment of addiction and insomnia

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2145922T3 (en)	1994-08-24	2000-07-16	Astrazeneca Ab	USEFUL SPYRO-AZABICYCLIC COMPOUNDS IN THERAPY.
SE9504661D0 (en)	1995-12-22	1995-12-22	Astra Pharma Inc	New compounds
SE9600683D0 (en)	1996-02-23	1996-02-23	Astra Ab	Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (en)	1997-07-18	2000-12-13	Astrazeneca Ab	SPYROZOBICYCLIC HETERO CYCLIC AMINES, PHARMACEUTICAL COMPOSITION, USE OF SUCH AMINES TO PREPARE MEDICINES AND METHOD OF TREATMENT OR PROPHYLAXIS
SE9702799D0 (en)	1997-07-25	1997-07-25	Astra Ab	New compounds
SE9900100D0 (en)	1999-01-15	1999-01-15	Astra Ab	New compounds
SE9903760D0 (en)	1999-10-18	1999-10-18	Astra Ab	New compounds
SE9904176D0 (en)	1999-11-18	1999-11-18	Astra Ab	New use
SE0000540D0 (en)	2000-02-18	2000-02-18	Astrazeneca Ab	New compounds
CN1814596A (en) *	2000-04-28	2006-08-09	阿卡蒂亚药品公司	Muscarinic agonists
SE0002729D0 (en)	2000-07-20	2000-07-20	Astrazeneca Ab	Novel compound form
IL158631A0 (en)	2001-05-18	2004-05-12	Astrazeneca Ab	4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
ATE353332T1 (en)	2001-06-01	2007-02-15	Astrazeneca Ab	NEW THERAPY-SUITABLE LIGAND FOR NICOTINIC ACETYLCHOLINE RECEPTORS
BR0309342A (en)	2002-04-18	2005-02-15	Astrazeneca Ab	Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions.
JP4511195B2 (en)	2002-04-18	2010-07-28	アストラゼネカ・アクチエボラーグ	Furyl compound
KR20040099446A (en)	2002-04-18	2004-11-26	아스트라제네카 아베	Heterocyclic compounds
SE0202465D0 (en)	2002-08-14	2002-08-14	Astrazeneca Ab	New compounds
SE0202430D0 (en)	2002-08-14	2002-08-14	Astrazeneca Ab	New Compounds
SE0202598D0 (en)	2002-09-02	2002-09-02	Astrazeneca Ab	Alpha-7 Nicotinic receptor agonists and statins in combination
JP2006523223A (en) *	2003-03-21	2006-10-12	イーライリリーアンドカンパニー	Muscarinic agonist
ATE478876T1 (en)	2004-10-25	2010-09-15	Lilly Co Eli	THIENOPYRIDINES AS ALLOSTERIC AMPLIFIERS OF THE M4 MUSCARINE RECEPTOR
EA200901101A1 (en) *	2007-02-20	2010-04-30	Новартис Аг	MACROCYCLIC COMPOUNDS AS INHIBITORS OF HCV PROTEASIS NS3
WO2012154731A1 (en)	2011-05-08	2012-11-15	Vanderbilt University	Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2013040534A1 (en)	2011-09-16	2013-03-21	Vanderbilt University	Substituted 1h-pyrazolo[3',4',4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulatiors of the muscarinic acetycholine receptor m4
ES2656972T3 (en)	2012-02-23	2018-03-01	Vanderbilt University	5-Aminothiene [2,3-c] pyridazin-6-carboxamide analogs as positive allosteric modulators of the M4 muscarinic acetylcholine receptor

2016
- 2016-10-04 GB GBGB1616839.5A patent/GB201616839D0/en not_active Ceased
2017
- 2017-10-04 WO PCT/JP2017/036899 patent/WO2018066718A1/en not_active Ceased

Also Published As

Publication number	Publication date
WO2018066718A1 (en)	2018-04-12

Publication	Publication Date	Title
SG10201912416QA (en)	2020-02-27	Therapeutic agents
GB201616839D0 (en)	2016-11-16	Therapeutic compounds
GB201509893D0 (en)	2015-07-22	Therapeutic agents
GB201517263D0 (en)	2015-11-11	Therapeutic agents
GB201415569D0 (en)	2014-10-15	Therapeutic Compounds
ZA201805046B (en)	2022-03-30	Therapeutic compounds
GB201603104D0 (en)	2016-04-06	Therapeutic agents
GB201716942D0 (en)	2017-11-29	Therapeutic compounds
GB201509885D0 (en)	2015-07-22	Therapeutic agents
GB201609597D0 (en)	2016-07-13	Therapy
GB201502412D0 (en)	2015-04-01	Therapeutic use
GB201608797D0 (en)	2016-07-06	Therapeutic use
GB201509888D0 (en)	2015-07-22	Therapeutic agents
GB201617339D0 (en)	2016-11-23	Therapeutic compounds
IL263821A (en)	2019-01-31	Therapeutic compounds
GB201513299D0 (en)	2015-09-09	Therapeutic agents
GB201416273D0 (en)	2014-10-29	Therapeutic compounds
GB201603653D0 (en)	2016-04-13	Combination Therapy
GB201617470D0 (en)	2016-11-30	Novel therapy
GB201521767D0 (en)	2016-01-27	Therapeutic agents
GB201600376D0 (en)	2016-02-24	Novel therapeutic agents
GB201517264D0 (en)	2015-11-11	Therapeutic agents
GB201506786D0 (en)	2015-06-03	Therapeutic use
GB201712884D0 (en)	2017-09-27	Novel therapeutic compounds
GB201618477D0 (en)	2016-12-14	Therapy

Legal Events

Date	Code	Title	Description
2018-02-07	AT	Applications terminated before publication under section 16(1)